Abstract

After publication of our article [1] we were notified that the data presented in the upper row of Fig. 7 was inadvertently the least square mean change from baseline (standard error) at Month 6 rather than the overall average of Month 3 and Month 6. The figure legend and discussion of the data in the text were and are correct. The error was only in the upper row of Fig. 7. The legend for Fig. 7 did not require revision.

Details

Title
Correction to: Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2)
Author
Silberstein, Stephen D 1 ; Stauffer, Virginia L 2 ; Day, Katie A 2 ; Lipsius, Sarah 3 ; Maria-Carmen, Wilson 4 

 Thomas Jefferson University, Jefferson Headache Center, Philadelphia, USA (GRID:grid.265008.9) (ISNI:0000 0001 2166 5843) 
 Lilly Corporate Center, Lilly Research Laboratories, Indianapolis, USA (GRID:grid.417540.3) (ISNI:0000 0000 2220 2544) 
 Syneos Health, Raleigh, USA (GRID:grid.492959.a) 
 Ochsner Health System, Covington, USA (GRID:grid.416735.2) (ISNI:0000 0001 0229 4979) 
Publication year
2019
Publication date
Dec 2019
Publisher
Springer Nature B.V.
ISSN
11292369
e-ISSN
11292377
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2330937582
Copyright
The Journal of Headache and Pain is a copyright of Springer, (2019). All Rights Reserved. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.